Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2Phase 1 1

Status

Active not recruiting 2Unknown 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Gastrointestinal 1

Conditions

Lymphoma, Primary Effusion 1Lymphoma, B-Cell 1Lymphoma, AIDS-Related 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Colorectal Neoplasms 1

Interventions

pembrolizumab 69Nivolumab 39Cyclophosphamide 35Carboplatin 27Dexamethasone 23Specimen Handling 22Paclitaxel 22Lenalidomide 22durvalumab 20Radiotherapy 19Gemcitabine 19venetoclax 18Magnetic Resonance Spectroscopy 18Doxorubicin 17Rituximab 16Ipilimumab 16fludarabine 15Bevacizumab 15Biopsy 14atezolizumab 13Etoposide 13Vincristine 12Cisplatin 12Azacitidine 12belantamab mafodotin 11Pemetrexed 11Docetaxel 11Calcium Dobesilate 11olaparib 10Oxaliplatin 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Active not recruiting × Endoscopy × Clear all
NCT05078866 2026-03-03

Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
45 enrolled
Gastrointestinal

Colorectal Neoplasms, Hereditary Nonpolyposis, Colorectal Neoplasms

NCT02911142 2025-07-28

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Active not recruiting
17 enrolled 21 charts
Lymphoid

Lymphoma, B-Cell, Lymphoma, AIDS-Related, Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡